FLT3 and acute myeloid leukemia: Furthermore, FLT3 has played a cardinal role in the study and management of AML since 1996, when Yokota et al., using reverse transcriptase-polymerase chain reaction (RT-PCR), found, in 5 AML patient samples (17%), a different transcript with a primer combination that could amplify the transmembrane (TM) domain through the juxtamembrane (JM) domain (FLT3-ITD mutation).